Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to fund the clinical development of Neurosterix’s lead program, which is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulators for the treatment of patients suffering from schizophrenia.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund II
Deal Size: $63.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 03, 2024